Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0340)
Name
1,2-Dioxolane
Synonyms
1,2-Dioxolane; 4362-13-4; 3H-1,2-Dioxole, dihydro-; DTXSID10195890

    Click to Show/Hide
Structure
Formula
C3H6O2
IUPAC Name
dioxolane
Canonical SMILES
C1COOC1
InChI
InChI=1S/C3H6O2/c1-2-4-5-3-1/h1-3H2
InChIKey
SNQXJPARXFUULZ-UHFFFAOYSA-N
PubChem CID
138198
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Fibrosarcoma ICD-11: 2B53
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model HT-1080 cells Fibrosarcoma Homo sapiens CVCL_0317
BJ1-hTERT cells Normal Homo sapiens CVCL_6573
BJ-eLR (Human fibroblast cancer cells)
Caki-1 cells Clear cell renal cell carcinoma Homo sapiens CVCL_0234
Response regulation FINO2 is an endoperoxide-containing 1,2-dioxolane that can initiate ferroptosis selectively in engineered cancer cells. FINO2 both indirectly inhibits GPX4 enzymatic function and directly oxidizes iron, ultimately causing widespread lipid peroxidation in Fibrosarcoma.
References
Ref 1 FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol. 2018 May;14(5):507-515. doi: 10.1038/s41589-018-0031-6. Epub 2018 Apr 2.